Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (March 2022)
44 slides from Windtree Therapeutics's investor presentation, Mar 31, 2022
Slide 1: Windtree Therapeutics Company Overview
Windtree Therapeutics Company Overview March 0 WINDTREE THERAPEUTICS (NASDA
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company'
Slide 3: Windtree Therapeutics Highlights
Windtree Therapeutics Highlights Biopharmaceutical company with advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ: WINT) Clinical programs focused on significant markets with high unmet needs G and with supportive regulatory paths: * One clinical program recei
Slide 4: Windtree Therapeutics Pipeline
Windtree Therapeutics Pipeline Lead Products [Phase of Development| Next Milestone FDA Fost Trock —Istaroxime Phase 25 * Study start up ongoing for second Phase Designation (Acute Heart Failure) 2b clinical trial in ~300 patients targeted to start once clinical trial operations are fully funded Pote
Slide 5: Strategy for Value Creation
Strategy for Value Creation Planned Milestones Early Cardiogenic | Early Cardiogenic Shock ‘Shock (ECS) Study ai |_Registration Study* Istaroxime S ECS Extension Stu Cardiogenic Shock SSE Istaroxime Acute Heart Failure Study Heart Failure (transition to Phase 3)** Wy ——eEe reg Oral SERCA2a Activator
Slide 6: Istaroxime
Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure and Early Cardiogenic Shocl
Slide 7: Heart Failure — Large, Growing Market But Underserved
Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing > 6MU.S., 20M+ worldwide patients v #1 cause of U.S. hospitalization in patients > 65 years old; * >1,3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) In-patient m
Slide 8: Acute Heart Failure — Significant Unmet Clinical Need
Acute Heart Failure — Significant Unmet Clinical Need ly ®" Clinical objectives for AHF = Current approaches to acutely improve patient management include: cardiac function are associated with * Relieve pulmonary congestion unwanted effects: and general edema (e.g., “dry * Heart rhythm disturbances
Slide 9: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action Ee 7 Inhibition of the sodium- SHIMUIBHON Of SERCAZA ACI enhances calcium reuptake resulting in potassium pumpandeffectson [StarOo
Slide 10: Istaroxime AHF Phase 2a & 2b Studies - Summary
Istaroxime AHF Phase 2a & 2b Studies - Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients SB Oh © n=120 Dosing= 6 hour Phase ja ADH Patients 0.5, 1, 1.5 nee/nin Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 0-5, 1.0 ug/g/min Infusion (dyspnea plus need for
Slide 11: Primary Endpoint Achieved
Primary Endpoint Achieved Significant Changes in E/e' Ratio) and Stroke Volume istaroxime 0.5 wg/kg/min vs. placebo istaroxime 1.0 yg/kg/min vs. placebo ao | 10 | Efe’ $3 | £0 Tafusion period | Satie +0 *pvalues <0.038 aa pale = 0.029 = fweine Shaws 2ehous—aBhours Beene Ghours hous Bors m-o= Plseto-
Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve
Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 pg/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo 2 ——— : i Systolic = g Blood == A Pressure = (SBP) é wt n\n a -9= Pceto Conor gem saroee0' hk min % Fa = 2 GFR (Renal Function) 2648 (l/mi
Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins
Heart Rate Decreased and No Increases in Cardiac Troponins istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 g/kg/min vs. placebo 3 5 5 ntustonsened 2 ol Heart qa Rate zs oo Pa * pwvalue= 0.018 Cas PP Pe oP go m-e- Poceno-conen ge teroinedsifia/nin sen Pcebo-cohen 2 ge nore 0 Helen cTnT-0 to 24 ho
Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring
Favorable Profile Observed with 24-hour Holter Monitoring cinta Significant. near Clinically Significant Arrhythmias ii 250% 200% na0% na0% 200% _ 0.0% poox - 100% a i rj | I 508 oon Beene Dey (rtton) seeing OeyA(htzon) 2 mpeceo-Conot —minwoximeDSuata/min smPacebo-cehot?—@iarme 0 uaKe/min Ventricula
Slide 15: Istaroxime — Acute Heart Failure Next Steps
Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally* -A_ _ Enrich therapeutic i
Slide 16: Istaroxime Early Cardiogenic Shock
Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development
Slide 17: Cardiogenic Shock
Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf
Slide 18: Early Cardiogenic Shock Treatment
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need > No satisfactory pharmacological intervention to reverse the conditions * Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction an
Slide 19: Early Cardiogenic Shock Treatment: Accelerated Pathway
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway FDA Regulatory Commentary with Break-Through Therapy Designation Potential Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drugs to treat h
Slide 20: Changes in SBP — Phase 2a and 2b Dose Groups
Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion : | a | ls | . 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change 0.5 ye/ke/min 1.0 g/kg/min 1.5 ug/kg/min Study/Dose ‘Mean SBP at Boseline “112 mmHg m6 Hours m24Hours
Slide 21: Early Cardiogenic Shock Study (SEISMiC Study)
Istaroxime Early Cardiogenic Shock Study (SEISMiC Study) SEISMIC Early Cardiogenic Shock Study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure 60 patient global study in early cardiogenic shock (SBP 75-90mmHg) with AHF 1.0 - 1.5ug/kg/min
Slide 22: SEISMIC Extension Study
SEISMIC Extension Study (amendment to the ECS study) Assuming positive results in the Early Cardiogenic Shock Study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology asso
Slide 23: Next Generation, Oral SERCA2a Activators
Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2Za Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & i.v. therapies for chronic heart = “Next generation Istaro
Slide 24: Summary: Potential to Create Value
Summary Potential to Create Value = Acute heart failure — large market with significant unmet need * Istaroxime appears to be the only drug in Phase 2 or Phase 3 development for AHF treatment = Istaroxime AHF—dual-mechanism therapy with positive Phase 2a and 2b trial outcomes: Y Improved cardiac fun
Slide 25: Lyo Lucinactant
Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in COVID-19 Patients Ay
Slide 26: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function
COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function Uses anglotendin: ACE2is surface molecule on Surfactant is necessary for lungs to Stay Increasedikelihood of converting enzyme 2 alveolarType 2lung cells~ inflated and for proper gas exchange; mechanical ventilat
Slide 27: Phase 2 Study of Lucinactant for COVID-19 ARDS
Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 ARDS Objective: Demonstrate safe and tolerable surfactant administration and changes in physiological parameters in COVID-19-associated lung injury and ARDS a * Open-label, single arm study in 20 patients from sites in US and La
Slide 28: AEROSURF
AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS) oe
Slide 29: Respiratory Distress Syndrome (RDS) Current Treatment Pathways
Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli
Slide 30: AEROSURF — Potential to Impact the Clinical Course of RDS
AEROSURF® — Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Long-Term Respiratory Outcomes Sia feauie show Parameters evidence of potential impact on clinical course of RDS and respiratory health of preterm infants
Slide 31: AEROSURF Program Evolution and Strategy
AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach “4 Execute small (n=~80 - 90) Bridging Study to transition to EOP2/Phase 3: * Demonstrate that new ADS works and supplement Phase 2 data Optimize dosing with more drug and shorter repeat intervals v Transitioned
Slide 32: Financial Summary & Capitalization as of December 31, 2021
Financial Summary & Capitalization as of December 31, 2021 = Cash & Equivalents of ~$22.3 million Common Equivalents pecuttes as of March 30, 2022 Common Stock 28,469,274 Options (WAEP $8.04) 4,173,033 Restricted Stock Units 554,000 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 49,825,1
Slide 33: Strategy for Value Generation
Strategy for Value Generation Strong Clinical Execution to Deliver Milestones: Execute well our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts GS Transactions: * Secure focused BD transactions for deal revenue and non-dilutive financial support
Slide 34: Windtree Therapeutics
Windtree Therapeutics
Slide 35: Appendix
Appendix
Slide 36: Acute Heart Failure
Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need * Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state
Slide 37: Istaroxime Phase 2a (HORIZON-HF) Study
Istaroxime Phase 2a (HORIZON-HF) Study Multicenter, double blind, placebo- controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU Hospitalized with AHF, with criteria including: LVEF < 35% * SBP 90-150 mmHg N=120 (30/group) Significant improvement in PCWP, SBP,
Slide 38: Istaroxime Phase 2b Adverse Events
Istaroxime Phase 2b Adverse Events istaroxime 0.5 Istaroxime 1.0 me/Ke/min me/Ke/min (n=41) (n=40) ‘All adverse events 23 (59.0%) 31 (75.6%) 33 (82.5%) ‘Adverse events leading to Pooled placebo (n=39) potastae 1 (2.6%) - 4 (10.0%) Serious adverse events 2 (51%) 214.9%) 6 (15.0%) Cardiac death = : 1(
Slide 39: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study
KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza * Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur
Slide 40: Evidence of KL4 Surfactant Potential Utility in COVID-19
Evidence of KL4 Surfactant Potential Utility in COVID-19 Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicability of KL4 surfactant for multiple etiologies of lung injury as well as pande: fluenza long before the COVID-19 pandemic Demonstrated Utility of KL4
Slide 41: Respiratory Distress Syndrome (RDS) Current Treatment Pathways
Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf
Slide 42: Windtree Technology Platform — AEROSURF
Windtree Technology Platform — AEROSURF® Proprietary Synthetic KL4 Surfactant Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLé surfactant (intratracheal instillate) ability to aerosolize KLs surfactant for RDS approved by the FDA Lyoph
Slide 43: Transformative Potential of AEROSURF
Transformative Potential of AEROSURF® Surfactant ‘CPAP. Therapy Respiratory Support Reversing surfactant deficiency has a profound positive impact on Avoids exposure tothe risks |) é respiration vfinvasivedelivery of py The benefits of traditional & - surfameanetherapy \-)) surfactant therapy withou
Slide 44: Business Development Focus
Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia Mid-term Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Out
Windtree Therapeutics — Investor Presentation (March 2022) on 6ix